Discovering The Potential Applications of Integrin Receptor (IR) as A Drug Target

Target Name: Integrin Receptor

NCBI ID: P12979

Integrin Receptor

Other Name(s): None

Discovering The Potential Applications of Integrin Receptor (IR) as A Drug Target

Integrin Receptor (IR) is a protein that is expressed in various tissues throughout the body. It plays a crucial role in cell-cell adhesion, which is the process by which cells stick together to form tissues and organs. IR is a subtype of integrin receptor, which is a family of transmembrane proteins that are involved in cell-cell adhesion. In this article, we will discuss the research on IR as a drug target and its potential applications in cancer treatment.

IR was first identified in the 1970s as a cell adhesion molecule. It is a monocistromeric protein that consists of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain of IR contains a N-terminal region that is involved in cell adhesion. This region contains a protein that is known as the interaction domain, which is responsible for interacting with other proteins that are involved in cell adhesion.

The transmembrane region of IR contains four transmembrane domains: an extracellular domain, a transmembrane domain, a cytoplasmic domain, and a nuclear domain. The cytoplasmic domain is responsible for interacting with the intracellular domain of IR. The nuclear domain is responsible for interacting with the DNA of the cell.

IR has been shown to play a crucial role in cell-cell adhesion. It is involved in the formation of tight junctions, which are a type of cell-cell adhesion that is responsible for maintaining tissue structure and function. tight junctions are formed by the interaction of IR with the cytoplasmic domain of other integrin receptors.

IR has also been shown to play a role in the regulation of cell migration. Integrin receptor is involved in the regulation of cell migration by interacting with the cytoplasmic domain of segrin which are also known as cadherins . IR has been shown to promote the migration of cancer cells through the regulation of the cytoplasmic domain of segmentation proteins.

Additionally, IR has been shown to play a role in the regulation of cell survival. Integrin receptor is involved in the regulation of cell survival by interacting with the intracellular domain of p53, which is a tumor suppressor gene that plays a critical role in regulating cell growth and apoptosis.

IR has also been shown to play a role in the regulation of cell signaling pathways. Integrin receptor is involved in the regulation of cell signaling pathways by interacting with various signaling molecules, including tyrosine kinase, which is a protein that is involved in cell signaling.

In conclusion, Integrin Receptor (IR) is a protein that is involved in various cellular processes throughout the body. It plays a crucial role in cell-cell adhesion, cell migration, and cell survival. As a result, IR is a potential drug target and a biomarker for various diseases, including cancer. Researchers are currently working on developing new drugs that can inhibit the activity of IR and enhance its activity to treat various diseases.

Protein Name: Integrin Receptor (nonspecified Subtype)

The "Integrin Receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Integrin Receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets